Potashman, Michele
Rudell, Katja
Pavisic, Ivanna
Suminski, Naomi
Doma, Rinchen
Heinrich, Maggie
Abetz-Webb, Linda
Beiner, Melissa Wolfe
Kuo, Sheng-Han
Rosenthal, Liana S.
Zesiwicz, Theresa
Fife, Terry D.
van de Warrenburg, Bart P.
Ristori, Giovanni
Synofzik, Matthis
Perlman, Susan
Schmahmann, Jeremy D.
L’Italien, Gilbert
Funding for this research was provided by:
This study was supported by Biohaven Pharmaceuticals, Inc.
Article History
Accepted: 29 April 2024
First Online: 7 May 2024
Declarations
:
: The study (BHV-4157-SCA-VAL) was approved by a centralized independent Institutional Review Board (IRB; Salus Institutional Review Board, Austin, TX, USA). IRB approval was not required for HCP interviews conducted in the United States or Europe. HCPs received consultancy fees for participating in the interviews.
: All eligible individuals with SCA and the HCPs provided informed consent to participate in the interviews and could withdraw at any time. The study was conducted in accordance with the 1964 Declaration of Helsinki.
: Michele Potashman, Melissa Wolfe Beiner, and Gilbert L’Italien are employed by, and own shares in, Biohaven Pharmaceuticals, Inc. Katja Rudell, Naomi Suminski, Rinchen Doma, and Maggie Heinrich are employees of Parexel and were commissioned by Biohaven Pharmaceuticals, Inc. to conduct the study. Ivanna Pavisic was an employee of Parexel until July 2023 and was commissioned by Biohaven Pharmaceuticals, Inc. to conduct the study. Sheng-Han Kuo, Theresa Zesiwicz, Bart van de Warrenburg, Liana S. Rosenthal, Terry D. Fife, Giovanni Ristori, Matthis Synofzik, and Susan Perlman received consultancy fees from Biohaven Pharmaceuticals, Inc. for participating in the interviews. Linda Abetz-Webb received consultancy fees from Parexel for this study. Sheng-Han Kuo has received consultancy fees from Biohaven Pharmaceuticals, Inc., Praxis Precision Medicines, and Sage Therapeutics. Theresa Zesiwicz has received personal compensation for serving on the advisory boards of Boston Scientific, Reata Pharmaceuticals, and Steminent Biotherapeutics; and received personal compensation as senior editor for Neurodegenerative Disease Management and as a consultant for Steminent Biotherapeutics. Royalties: royalty payments as co-inventor of varenicline for treating imbalance and nonataxic imbalance. Grants: research grant support as Principal Investigator for studies from AbbVie, Biogen, Biohaven Pharmaceuticals, Inc., Boston Scientific, Bukwang Pharmaceuticals Co, Inc., Cala Health, Inc., Cavion, Friedreich’s Ataxia Research Alliance; Houston Methodist Research Institute, National Institutes of Health, REtrotope Inc, and Takeda Development Center Americas, Inc. Bart P. van de Warrenburg has served on advisory boards and/or as consultant for Servier, Vico Therapeutics, Biohaven Pharmaceuticals, Inc., and uniQure. Royalties: BSL—Springer Nature. Grants: Radboud University Medical Center, ZonMw, Gossweiler Foundation, Hersenstichting, NWO, and Christina Foundation. Jeremy D. Schmahmann has served on the editorial board for The Cerebellum, Editorial Board, 1999. Consultancy: Biohaven Pharmaceuticals, Inc. Site Principal Investigator: Biohaven Pharmaceuticals, Inc. clinical trials in ataxia and multiple system atrophy. Research support, commercial entities: Biohaven Pharmaceuticals, Inc. support of clinical trials. Research support, academic entities: National Ataxia Foundation. Research support, foundations, and societies: National Ataxia Foundation, 2019, Principal Investigator license fee payments. Technology or inventions: Brief Ataxia Rating Scale (BARS) and Brief Ataxia Rating Scale revised (BARS2). Copyright held by The General Hospital Corporation. Cerebellar Cognitive Affective/Schmahmann syndrome Scale. Copyright held by The General Hospital Corporation. Patient-Reported Outcome Measure of Ataxia. Copyright held by The General Hospital Corporation. Cerebellar Neuropsychiatric Rating Scale. Copyright held by The General Hospital Corporation.